Havn Life

Havn Life was a biotech company that aimed to produce GPM-level psilocybin and sell other (fungi based) healthcare products.

Havn Life

“Havn Life is a biotechnology company aimed at improving cognitive performance through the standardized extraction of psychoactive compounds and the development of natural health care products from novel compounds.”

Havn has two divisions that aim to bring their products to market. The first, Havn Retail, will focus on providing mushroom (and psilocybin) products to consumers. The second, Havn Labs, aims to provide clinical (GPM) grade psilocybin (and possibly other compounds) to labs, universities, and centres.

The company is publicly listed (CSE, September 2020), but people on Twitter are critical and question the longevity of the company and its co-CEOs.

In December 2020, Havn announced the closure of its IPO for a total of U$9.2 million.

The company recently (February 2021) partnered with HealthTech Connex, and will provide the psilocybin for their (future) clinical trials.

In September 2022, the company announced it didn’t have any more money left to continue operations.

News

• Havn Life Announces Strategic Clinical Trial Partnership With Healthtech Connex Inc (press release, February 2021)
• Psychedelic stocks: HAVN gets off to a good start, Numinus shares in a funk, and COMPASS prepares to go public (Straight, September 2020)
• Meet the Woman Who Wants to Sell Psychedelic Drugs to Scientists (Futurism, August 2020)